Breaking News Instant updates and real-time market news.

MRK

Merck

$61.66

-0.27 (-0.44%)

06:47
10/13/16
10/13
06:47
10/13/16
06:47

Merck upgraded to Buy from Neutral at BofA/Merrill

BofA/Merrill analyst Colin Bristow upgraded Merck to Buy and raised its price target to $70 from $57 to reflect its opportunity in first line lung cancer. Bristow significantly raised his Keytruda sales estmate to 7.5B from $5.5B following Merck's first line lung cancer data presentations at ESMO over the weekend and feedback from experts. He expects Keytruda to receive early approval/launch in first line NSCLC from the December 24 PDUFA and to become the standard of care in the identified label and further upside from chemo combo.

  • 25

    Oct

  • 06

    Nov

MRK Merck
$61.66

-0.27 (-0.44%)

10/10/16
LEER
10/10/16
NO CHANGE
LEER
Outperform
Leerink sees Bristol-Myers sliding after Merck's 'spectacular' Keytruda data
Leerink analyst Seamus Fernandez said Bristol-Myers' (BMY) Checkmate-026 data presented at the European Society of Medical Oncology meeting was disappointing, noting there was no signal of benefit on progression-free survival or overall survival and only "modest differentiation" on response rate in the 88 patients with PDL1 biomarker positivity greater than or equal to 50%. Meanwhile, Merck (MRK) presented "spectacular" data for Keytruda monotherapy at the meeting, said Fernandez, who expects Bristol shares to be down "significantly" today in light of the meeting presentations. The analyst, who still thinks Bristol has a significant opportunity to compete with Merck's Keytruda in the PDL1 high portion of the market, keeps an Outperform rating on Bristol shares, which are down nearly 6% in pre-market trading.
10/10/16
BMOC
10/10/16
NO CHANGE
BMOC
Merck should strengthen leadership in first line NSCLC, says BMO Capital
BMO Capital analyst Alex Arfaei says that upcoming data should strengthen Merck's (MRK) lead in 1L NSCLC. The analyst adds that the data could support off-label use of Merck's Keytruda in additional 1L NSCLC patients, and he says that the data "should be negative" for Bristol-Myers' (BMY) Opdivo drug. Arfaei keeps an Outperform rating on Merck and a Market Perform rating on Bristol-Myers.
10/10/16
LEER
10/10/16
NO CHANGE
LEER
Market Perform
Merck 'steals the show' at ESMO with Keytruda data, says Leerink
Leerink analyst Seamus Fernandez said Merck (MRK) stole the show at ESMO with its Keytruda data and he continues to think the company will dominate first line lung cancer treatment for years to come in patients with 50%+ PDL1 expression. Additionally, he expects Merck to gain additional traction in the overall market, noting that confirmation that Keytruda is benefiting patients when combined with Alimta/carboplatin with Alimta maintenance raises the possibility Merck could compete broadly in the overall non-squamous patient population. However, Fernandez keeps a Market Perform rating on Merck, as he thinks its current valuation largely reflects improved growth prospects through 2020.
10/10/16
JMPS
10/10/16
NO CHANGE
JMPS
Incyte treatment looking 'promising,' says JMP Securities
After reviewing recent data, JMP Securities analyst Liisa Bayko says that the combination of Incyte's (INCY) Epacadostat plus Merck's (MRK) Keytruda is "emerging as a promising treatment, potentially even best in class." The analyst says that the progression free survival rate of the combination in melanoma patients "is emerging to be quite competitive," while the efficacy rate in other solid tumors "seemed encouraging." The analyst raised her price target on Incyte to $110 from $100 and keeps an Outperform rating on the stock.

TODAY'S FREE FLY STORIES

SLV

iShares Silver Trust

$17.41

0.17 (0.99%)

12:11
02/24/17
02/24
12:11
02/24/17
12:11
Options
Sizable four-way spread in the Silver Fund as a bullish option play is adjusted »

Sizable four-way spread…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FNB

F.N.B.

$15.52

-0.15 (-0.96%)

, YDKN

Yadkin Financial

$33.15

-0.415 (-1.24%)

12:03
02/24/17
02/24
12:03
02/24/17
12:03
Periodicals
Federal Reserve clears F.N.B.'s takeover of Yadkin, Reuters reports »

The Federal Reserve has…

FNB

F.N.B.

$15.52

-0.15 (-0.96%)

YDKN

Yadkin Financial

$33.15

-0.415 (-1.24%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NVDA

NVIDIA

$100.49

-10.27 (-9.27%)

12:01
02/24/17
02/24
12:01
02/24/17
12:01
Options
Heavy trading in Nvidia short-term options as shares stage an aggressive rebound »

Heavy trading in Nvidia…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Feb

  • 05

    Mar

  • 16

    Mar

  • 20

    Mar

12:00
02/24/17
02/24
12:00
02/24/17
12:00
General news
Treasury Option Action: a round of put activity »

Treasury Option Action: a…

ONCS

OncoSec

$1.42

-0.1 (-6.58%)

11:59
02/24/17
02/24
11:59
02/24/17
11:59
Conference/Events
OncoSec to hold KOL Event Focused on New ASCO-SITC Melanoma Data »

OncoSec's Chief…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MGEN

Miragen Therapeutics

$13.99

-0.06 (-0.43%)

11:55
02/24/17
02/24
11:55
02/24/17
11:55
Hot Stocks
Boulder Ventures V reports 9.9% stake in Miragen Therapeutics »

According to a regulatory…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MTG

MGIC Investment

$10.55

-0.055 (-0.52%)

11:51
02/24/17
02/24
11:51
02/24/17
11:51
Options
MGIC Investment with 11.5X average daily optoin volume driven by a bullish play »

MGIC Investment with…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

WLL

Whiting Petroleum

$11.06

-0.09 (-0.81%)

11:46
02/24/17
02/24
11:46
02/24/17
11:46
Options
Whiting Petroleum call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    Mar

11:45
02/24/17
02/24
11:45
02/24/17
11:45
Conference/Events
Leerink analysts hold an analyst/industry conference call »

In conjunction with the…

11:40
02/24/17
02/24
11:40
02/24/17
11:40
General news
NY Fed Nowcast has Q1 GDP at 3.12% »

NY Fed Nowcast has Q1 GDP…

SPWR

SunPower

$8.99

0.53 (6.26%)

11:36
02/24/17
02/24
11:36
02/24/17
11:36
Options
SunPower put volume heavy and directionally bearish »

Bearish flow noted in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

IDRA

Idera Pharmaceuticals

$1.73

0.05 (2.98%)

11:33
02/24/17
02/24
11:33
02/24/17
11:33
Hot Stocks
Idera says achieved 'successful' completion of objectives in Phase 1 trial »

Idera Pharmaceuticals is…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TRIL

Trillium Therapeutics

$5.90

-0.1 (-1.67%)

11:32
02/24/17
02/24
11:32
02/24/17
11:32
Hot Stocks
Trillium Therapeutics: New TTI-621 data advances understanding of product »

Trillium Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

VISI

Volt Information Sciences

$7.35

-0.1 (-1.34%)

, CCRN

Cross Country Healthcare

$15.89

-0.37 (-2.28%)

11:32
02/24/17
02/24
11:32
02/24/17
11:32
Hot Stocks
Volt Information Sciences reports nomination of new independent directors »

Volt Information Sciences…

VISI

Volt Information Sciences

$7.35

-0.1 (-1.34%)

CCRN

Cross Country Healthcare

$15.89

-0.37 (-2.28%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    Mar

  • 08

    Mar

  • 14

    Mar

  • 21

    Mar

MCO

Moody's

$112.59

-0.64 (-0.57%)

11:31
02/24/17
02/24
11:31
02/24/17
11:31
Conference/Events
Leerink analysts hold an analyst/industry conference call »

Analysts provide a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    Mar

  • 05

    Mar

VIVHY

Vivendi

$17.95

-0.06 (-0.33%)

, MDIUY

Mediaset

11:28
02/24/17
02/24
11:28
02/24/17
11:28
Periodicals
Milan prosecutors investigating Vivendi over alleged stock manipulation, FT says »

Milan prosecutors are…

VIVHY

Vivendi

$17.95

-0.06 (-0.33%)

MDIUY

Mediaset

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FSLR

First Solar

$37.19

3.62 (10.78%)

11:26
02/24/17
02/24
11:26
02/24/17
11:26
Options
First Solar call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Mar

GS

Goldman Sachs

$247.19

-4 (-1.59%)

11:23
02/24/17
02/24
11:23
02/24/17
11:23
Periodicals
Goldman Sachs exec involved in 1MDB dealings leaves bank, WSJ says »

A senior Goldman Sachs…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    Mar

ALNY

Alnylam

$46.25

0.3 (0.65%)

11:22
02/24/17
02/24
11:22
02/24/17
11:22
Conference/Events
JPMorgan SMid biotech analyst holds an analyst/industry conference call »

SMid Biotech Analyst…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Feb

$NSD

NASDAQ Market Internals

11:17
02/24/17
02/24
11:17
02/24/17
11:17
Technical Analysis
NASDAQ market internals summary »

Volume is above average…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NYE

NYSE Market Internals

11:16
02/24/17
02/24
11:16
02/24/17
11:16
Technical Analysis
NYSE market internals summary »

Volume is above average…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MBLY

Mobileye

$46.96

-1.18 (-2.45%)

11:16
02/24/17
02/24
11:16
02/24/17
11:16
Options
Mobileye put volume heavy and directionally bearish »

Bearish flow noted in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Mar

HBI

Hanesbrands

$20.96

0.04 (0.19%)

11:12
02/24/17
02/24
11:12
02/24/17
11:12
Conference/Events
Hanesbrands management to meet with Oppenheimer »

Meeting to be held in New…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    Mar

WIX

Wix.com

$63.25

-2.3 (-3.51%)

11:10
02/24/17
02/24
11:10
02/24/17
11:10
Conference/Events
Wix.com management to meet with Oppenheimer »

Meetings to be held on…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Feb

  • 01

    Mar

  • 02

    Mar

SNCR

Synchronoss

$30.86

-0.03 (-0.10%)

11:09
02/24/17
02/24
11:09
02/24/17
11:09
Periodicals
Synchronoss has withheld 'a great deal' about 'transformation,' SIRF says »

Synchronoss Technologies…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.